Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats

Journal of Ethnopharmacology

Volumn 113, Issue 2, 2007, Pages 318-324

  Ji, W ^a   Gong, B Q ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Farnesoid X receptor; Hypolipidemic; Liver X receptor ; Panax notoginsen

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN C3; BUTANOL; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; FARNESOID X RECEPTOR; LIPID; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PANAX NOTOGINSENG EXTRACT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL;

AGONIST; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; EXPERIMENTAL RAT; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPOLIPIDEMIC ACTIVITY; INHIBITION KINETICS; LIPID ANALYSIS; LIPID DIET; LIPID METABOLISM; LOW DRUG DOSE; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; ANTILIPEMIC AGENTS; BUTANOLS; CELL LINE, TUMOR; CHOLESTEROL; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; GENE EXPRESSION; HEXANES; HUMANS; HYPERLIPIDEMIAS; LIVER; MALE; PANAX NOTOGINSENG; PLANT EXTRACTS; PLANT ROOTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSFECTION; TRIGLYCERIDES;

ANIMALIA; PANAX; PANAX NOTOGINSENG; RATTUS;

EID: 34547791216     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2007.06.022     Document Type: Article

References (41)

1. Aldons J.L. Atherosclerosis. Nature 407 (2000) 233-241
2. Antonios M., Xydakis M.D., Christie M., and Ballantyne M.D. Combination therapy for combined dyslipidemia. American Journal of Cardiology 90 (2002) 21K-29K
3. Attie A.D., Kastelein J.P., and Hayden M.R. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. Journal of Lipid Research 42 (2001) 1717-1726
4. Beyer T.P., Schmidt R.J., Foxworthy, Patricia, Zhang Y.Y., Dai J.N., Bensch W.R., Kauffman R.F., Gao H., Ryan T.P., Jiang X.C., Karathanasis S.K., Eacho P.I., and Cao G.Q. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-A agonist in mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. Journal of Pharmacology and Experimental Therapeutics 309 (2004) 861-868
5. Bilheimer D.W., Grundy S.M., Brown M.S., and Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proceedings of the National Academy of Sciences USA 80 (1983) 4124-4218
6. Brown M.S., and Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 232 (1986) 34-47
7. Cicero A.F.G., Vitale G., Savino G., and Arletti R. Panax notoginseng (Burk.) effects on fibrinogen and lipid plasma level in rats fed on a high-fat diet. Phytotherapy Research 17 (2003) 174-178
8. Claudel T., Inoue Y., Barbier O., Duran-Sandoval D., Kosykh V., Fruchart J., Fruchart J.C., Gonzalez F.J., and Staels B. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125 (2003) 544-555
9. Claudel T., Staels Bart., and Kuipers F. The Farnesoid X Receptor A molecular link between bile acid and lipid and glucose metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology 25 (2005) 2020-2031
10. Claudel T., Sturm E., Duez H., Torra I.P., Sirvent A., Kosykh V., Fruchart J.C., Dallongeville J., Hum D.W., Kuipers F., and Staels B. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. Journal of Clinical Investigation 109 (2002) 961-971
11. Delerive P., Galardi C.M., Bisi J.E., Nicodeme E., and Goodwin B. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. Molecular Endocrinology 18 (2004) 2378-2387
12. Feng P.F., Qin N.P., and Qiao Q. Clinical and experimental study of improving left ventricular diastolic function by total saponins of Panax notoginseng. Chung Kuo His I Chieh HO Tsa Chih 17 (1999) 714-717
13. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Journal of the American Medical Association 287 (2002) 356-359
14. Goldberg I.J., Scheraldi C.A., Yacoub L.K., Saxena U., and Bisgaier C.L. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. Journal of Biological Chemistry 265 (1990) 4266-4272
15. Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., Galardi C., Wilson J.G., Lewis M.C., Roth M.E., Maloney P.R., Willson T.M., and Kliewer S.A. A regulatory cascade of the nuclear receptors FXR, SHP-l, and LRH-1 represses bile acid biosynthesis. Molecular Cell 6 (2000) 517-526
16. Graf G.A., Li W.P., Gerard R.D., Gelissen, Ingrid, White A., Cohen J.C., and Hobbs H.H. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. Journal of Clinical Investigation 110 (2002) 659-669
17. Heid C.A., Stevens J., Livak K.J., and Williams P.M. Real time quantitative PCR. Genome Research 6 (1996) 986-994
18. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation 109 (2002) 1125-1131
19. Kast H.R., Nguyen C.M., Sinal C.J., Jones S.A., Laffitte B.A., Reue K., Gonzalez F.J., Willson T.M., and Edwards P.A. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Molecular Endocrinology 15 (2001) 1720-1728
20. Kovanen P.T., and Schneider W.J. Regulation of the low density lipoprotein (B/E) receptor. Advances in Vascular Biology 5 (1999) 165-185
21. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.-L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., and Willson T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. Journal of Biological Chemistry 272 (1997) 3137-3140
22. Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., Auwerx J., and Mangelsdorf D.J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Molecular Cell 6 (2000) 507-515
23. Lu T.T., Repa J.J., and Mangelsdorf D.J. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. Journal of Biological Chemistry 41 (2001) 37735-37738
24. Ma P.T.S., Gil G., Sudhof T.C., Bilheimer D.W., Goldstein J.L., and Brown M.S. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in liver of hamsters and rabbits. Proceedings of the National Academy of Sciences USA 83 (1986) 8370-8374
25. NCEP, 2002. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421.
26. Ninomiya J.K., L'Italien G., Criqui M.H., Whyte J.L., Gamst A., and Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation 109 (2004) 42-46
27. Nitta M., Ku S., Brown C., Okamoto A.Y., and Shan B. CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene. Proceedings of the National Academy of Sciences USA 96 (1999) 6660-6665
28. Princen H.M.G., Post S.M., and Twisk J. Regulation of bile acid biosynthesis. Current Pharmaceutical Design 3 (1997) 59-84
29. Raalte D.H., Li M., Pritchard P.H., and Wasan K.M. Peroxisome proliferator-activated receptor (PPAR)-α: a pharmacological target with a promising future. Pharmaceutical Research 9 (2004) 1531-1538
30. Repa J.J., Berge K.E., Pomajzl C., Richardson J.A., Hobbs H., and Mangelsdorf D.J. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors α and β. Journal of Biological Chemistry 277 (2002) 18793-18800
31. Repa J.J., Liang G.S., Ou J., Bashmakov Y., Lobaccaro J.A., Shimomura I., Shan Bei., Brown M.S., Goldstein J.L., and Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXR-α and LXR-β. Genes Development 14 (2000) 2819-2830
32. Repa J.J., and Mangelsdorf D.J. The liver X receptor gene team: potential new players in atherosclerosis. Nature Medicine 11 (2002) 1243-1248
33. Sambrook J., and Russell D.W. Molecular Cloning: A Laboratory Manual. 3rd ed. (2001), Cold Spring Harbor Laboratory Press
34. Schultz J.R., Tu Hua., Luk A., Repa J.J., Medina J.C., Li L.P., Schwendner S., Wang S., Thoolen Martin, Mangelsdorf D.J., Lustig K.D., and Shan B. Role of LXRs in control of lipogenesis. Genes Development 14 (2000) 2831-2838
35. Staels B., Vu-Dac N., Kosykh V.A., Saladin R., Fruchart J.C., Dallongeville J., and Auwerx J. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomalacyl co-enzyme A oxidase. Journal of Clinical Investigation 65 (1995) 705-712
36. Watanabe M., Houten S.M., Wang L., Moschetta, Antonio, Mangelsdorf D.J., Heyman R.A., Moore D.D., and Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. Journal of Clinical Investigation 113 (2004) 1408-1418
37. Yoshikawa M., Murakami T., Ueno T., Hirokawa N., Yashiro K., Murakami N., Yamahara J., Matsuda H., Saijoh R., and Tanaka O. Bioactive saponins and glycosides. IX. Notoginseng (2) Structures of five new dammarane-type triterpene oligoglycosides, notoginseno-sides-E, -G, -H, -I and -J, and a novel acetylenic fatty acid glycoside, notoginsenic acid β-sophoroside, from the dried. Chemical and Pharmaceutical Bulletin 45 (1997) 1056-1062
38. Yoshikawa M., Murakami T., Ueno T., Hirokawa N., Yashiro K., Murakami N., Yamahara J., Matsuda H., Saijoh R., and Tanaka O. Bioactive saponins and glycosides. VIII. Notoginseng (1) new dammarane-type triterpene oligoglycosides, notoginsenosides-A, -B, -C, and -D, from the dried root of Panax notoginseng. Chemical and Pharmaceutical Bulletin 45 (1997) 1039-1045
39. Zhao P., Liu Y.Q., and Yang C.R. Minor dammarane saponins from Panax notoginseng. Phytochemistry 41 (1996) 1419-1422
40. Zhang W.J., Wojta J., and Binder B.R. Effect of notoginsenosides R1, on the systhesis of components of the fibrinolytic system in cultured smooth muscle cells of human pulmonary artery. Cell and Molecular Biology 43 (1997) 581-587
41. 4-3-ketone derivatives by HPLC and response to physiological perturbations. Journal of Lipid Research 42 (2001) 649-658